CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
Join us on June 25, 2016, for a one-day, multi-distance “Answer to Cancer” cycling event throughout New York's Lower Hudson Valley and sponsored by Bristol-Myers Squibb.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can slow progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, accelerating promising new immunotherapies for patients.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Cancer Immunotherapy and You" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
June 7, 2016
Arthur N. Brodsky, Ph.D.
New strategies use alternative ways to promote anti-cancer immunity.
ASCO, bladder cancer, checkpoint-inhibitor, colorectal cancer, kidney cancer, melanoma
ASCO, CAR T cell therapy, checkpoint-inhibitor, leukemia, lung cancer, lymphoma
Anti-PD-1 blockade and two other types of immunotherapy effective in treating multiple tumor types.
AACR, checkpoint-inhibitor, head and neck cancer, skin cancer
AACR, checkpoint-inhibitor, combination therapy
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung cancer.
checkpoint-inhibitor, FDA approval, lung cancer, PD-1
anti-CTLA-4, checkpoint-inhibitor, combination therapy, FDA approval, melanoma
One of the most prestigious prizes in biology, the Lasker is considered a precursor to the Nobel.
awards & honors, checkpoint-inhibitor, James Allison, scientific leadership
checkpoint-inhibitor, clinical trials, melanoma